FlandersBio on Twitter

Follow us on Twitter

Archive for June 2013 - News

Archive for June 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

PathoGenetix and Applied Maths to Integrate Rapid Strain Typing and Bioinformatics Tools


PathoGenetix, Inc. and Applied Maths, NV have signed an agreement to link the RESOLUTION Microbial Genotyping System with the BioNumerics software suite to offer a dramatically improved time-to-answer and shortened decision making time in pathogen outbreak investigations, traceback and epidemiological response. The fully automated and integrated solution will confirm and identify pathogens in complex mixtures in just five hours, allow rapid sharing of outbreak information among public health and food safety laboratories, and enable comparison to strain data from other typing systems such as pulsed field gel electrophoresis (PFGE). read more

Minister Geens 'denkt na' over taxshelter voor biotech


Chris Buyse, de CFO van het Leuvense ThromboGenics, pleit voor een taxshelter voor biotechbedrijven. read more

Establishment of the Walloon Cell Therapy Platform - The platform aims to produce cell therapy medicines on a large scale


The foundation stone of the Walloon Cell Therapy Platform in Gosselies (Belgium) was laid. This platform will allow large-­‐scale production of celltherapy medicines and has been established thanks to a public-­‐private partnership. The Walloon Region and Sambrinvest contribute to the industrial renewal of the region and two private cell therapy companies -­‐ Bone Therapeutics and Promethera Biosciences – invest, to start production of their medicines in the new premises from 2015. The platform, unique in this category, provides Wallonia with a new and particularly innovative high-­‐tech cluster to respond to the development needs of the growing number of cell therapy companies in Belgium. read more

Complix raises €12 million (US$ 15.5 million) in Series B round


Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics active against intracellular disease targets, announces the successful closing of a €12 million (US$15.5 million) Series B equity financing round from a syndicate of leading life sciences investors. The fundraising was co-led by new investors Edmond de Rothschild Investment Partners (France) and Gimv (Belgium) and Biotech Fund Flanders (managed by Gimv). Existing shareholders LRM, OMNES Capital, Vesalius Biocapital, Gemma Frisius Fund, TrustCapital, Vinnof, Baekeland Fund, CRP-Santé and management also participated in this round. read more

Multiplicom appoints Dr. Ian Gilham as Chairman of the Board


Niel, Belgium, Multiplicom NV, a specialist in the development, production and commercialisation of innovative molecular genetic tests, today announces that Dr Ian Gilham has been appointed as Chairman of the Board of Directors. read more

MDxHealth Completes €18 Million ($24M) Equity Raise


MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, announced today that it successfully raised an aggregate amount of €18 million in a private placement through the issuance of 8,737,683 new shares at a subscription price of EUR 2.06 per share (which represents the average closing price of the company's shares during the 30 preceding calendar days). Certain funds managed by Valiance Asset Management Ltd participated in the private placement for a total amount of 4,368,932 new shares and Biovest Comm. VA, the investment company of Rudi Mariën, participated in the private placement for a total amount of 2,427,184 new shares. The remaining 1,941,747 new shares were underwritten by Petercam who acted as sole lead manager in the transaction, and will be placed with a limited group of investors. read more

Cryo-Save Group N.V. - Board change


Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that Mr Johan Goossens decided to step back from office as a Non-Executive Board Member with immediate effect. read more

Amakem Appoints Kieran Rooney as Vice President, Business Development


Amakem NV, a clinical stage ophthalmology company, today announces that it has appointed Dr. Kieran Rooney as Vice President, Business Development. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top